Skip to content
Triangle logo TriangleGet started
← Study library

NCT01824693 · REGISTRY CONDITION SEARCH

Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
COMPLETED
Registry last update
2018-12-05

This randomized phase II trial studies how well giving busulfan, cyclophosphamide, and melphalan or busulfan and fludarabine phosphate before donor hematopoietic cell transplant works in treating younger patients with juvenile myelomonocytic leukemia. Giving chemotherapy before a donor hematopoietic transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient, they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. It is not yet known whether giving busulfan, cyclophosphamide, and melphalan or busulfan and fludarabine phosphate before a donor stem cell transplant is more effective in treating juvenile myelomonocytic leukemia.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Percent Probability of Event-free Survival (EFS)

→

outcome · POSTED

Number of Participants Who Experience Treatment-Related Mortality (TRM) by Day 100

→

outcome · POSTED

Percentage of Participants Who Experience Primary Graft Failure Event Between Arms

→

outcome · POSTED

Percent Probability of 18 Months-relapse Event Between Arms

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Patients must have a strong clinical suspicion of JMML, based on a modified category 1 of the revised diagnostic criteria; specifically, eligible patients must have all of the following: * Splenomegaly * Absolute monocyte count (AMC) \> 1000/uL * Blasts in peripheral blood (PB)/bone marrow (BM) \< 20% * For the 7-10% of patients without splenomegaly, the diagnostic entry criteria must include all other features described above and at least 2 of the following criteria: * Circulating myeloid precursors * White blood cell (WBC) \> 10,000/uL * Increased fetal hemoglobin (HgbF) for age * Sargramostim (GM-CSF) hypersensitivity OR, patients must have been previously diagnosed with JMML * Patients must be previously untreated with HCT * All patients and/or their parents or legal guardians must sign a written informed consent * All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met Exclusion Criteria: * Patients with a known germline mutation of PTPN11 (Noonan?s Syndrome) are not eligible * Patients with a known history of NF1 (Neurofibromatosis Type 1) and either * A history of a tumor of the central nervous system (astrocytoma or optic glioma), or * A malignant peripheral nerve sheath tumor with a complete remission of \< 1 year are not eligible * Human immunodeficiency virus (HIV) positive patients are not eligible
healthy Volunteers
false
maximum Age
18 Years
minimum Age
3 Months
sex
ALL
std Ages
  1. CHILD
  2. ADULT
Treatment arms and interventions
arm Groups
  1. description
    CONDITIONING REGIMEN: Patients receive busulfan IV QD, every 12 hours, or every 6 hours over 2-3 hours on days -8 to -5, cyclophosphamide IV QD over 60 minutes on days -4 and -3, and melphalan IV over 15-30 minutes on day -1. TRANSPLANT: Patients undergo allogeneic HCT no sooner than 24 hours after the last dose of chemotherapy. Patients receive tacrolimus IV or PO on days -1 to 98 (related donor) or 180 (unrelated donor) and mycophenolate mofetil IV over 2 hours or PO every 8 hours on days 1-30 (related donor) or 45 (unrelated donor).
    intervention Names
    1. Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
    2. Drug: Busulfan
    3. Drug: Cyclophosphamide
    4. Other: Laboratory Biomarker Analysis
    5. Drug: Melphalan
    6. Drug: Mycophenolate Mofetil
    7. Other: Pharmacological Study
    8. Drug: Tacrolimus
    label
    Arm I (busulfan, cyclophosphamide, melphalan)
    type
    EXPERIMENTAL
  2. description
    CONDITIONING REGIMEN: Patients receive busulfan as in Arm I and fludarabine phosphate IV over 1 hour on days -5 to -2. TRANSPLANT: Patients undergo allogeneic HCT as in Arm I. Patients receive tacrolimus IV or PO on days -1 to 98 (related donor) or 180 (unrelated donor) and mycophenolate mofetil IV over 2 hours or PO every 8 hours on days 1-30 (related donor) or 45 (unrelated donor).
    intervention Names
    1. Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
    2. Drug: Busulfan
    3. Drug: Fludarabine Phosphate
    4. Other: Laboratory Biomarker Analysis
    5. Drug: Mycophenolate Mofetil
    6. Other: Pharmacological Study
    7. Drug: Tacrolimus
    label
    Arm II (busulfan, fludarabine phosphate)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Arm I (busulfan, cyclophosphamide, melphalan)
    2. Arm II (busulfan, fludarabine phosphate)
    description
    Undergo allogeneic HCT
    name
    Allogeneic Hematopoietic Stem Cell Transplantation
    other Names
    1. Allogeneic Hematopoietic Cell Transplantation
    2. Allogeneic Stem Cell Transplantation
    3. HSC
    4. HSCT
    type
    PROCEDURE
  2. arm Group Labels
    1. Arm I (busulfan, cyclophosphamide, melphalan)
    2. Arm II (busulfan, fludarabine phosphate)
    description
    Given IV
    name
    Busulfan
    other Names
    1. 1, 4-Bis[methanesulfonoxy]butane
    2. BUS
    3. Bussulfam
    4. Busulfanum
    5. Busulfex
    6. Busulphan
    7. CB 2041
    8. CB-2041
    9. Glyzophrol
    10. GT 41
    11. GT-41
    12. Joacamine
    type
    DRUG
  3. arm Group Labels
    1. Arm I (busulfan, cyclophosphamide, melphalan)
    description
    Given IV
    name
    Cyclophosphamide
    other Names
    1. (-)-Cyclophosphamide
    2. 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate
    3. Carloxan
    4. Ciclofosfamida
    5. Ciclofosfamide
    6. Cicloxal
    7. Clafen
    8. Claphene
    9. CP monohydrate
    10. CTX
    11. CYCLO-cell
    12. Cycloblastin
    type
    DRUG
  4. arm Group Labels
    1. Arm II (busulfan, fludarabine phosphate)
    description
    Given IV
    name
    Fludarabine Phosphate
    other Names
    1. 2-F-ara-AMP
    2. 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-
    3. Beneflur
    4. Fludara
    5. SH T 586
    type
    DRUG
  5. arm Group Labels
    1. Arm I (busulfan, cyclophosphamide, melphalan)
    2. Arm II (busulfan, fludarabine phosphate)
    description
    Correlative studies
    name
    Laboratory Biomarker Analysis
    type
    OTHER
  6. arm Group Labels
    1. Arm I (busulfan, cyclophosphamide, melphalan)
    description
    Given IV
    name
    Melphalan
    other Names
    1. Alanine Nitrogen Mustard
    2. CB-3025
    3. L-PAM
    4. L-Phenylalanine Mustard
    5. L-sarcolysin
    6. L-Sarcolysin Phenylalanine mustard
    7. L-Sarcolysine
    8. Melphalanum
    9. Phenylalanine Mustard
    10. Phenylalanine nitrogen mustard
    11. Sarcoclorin
    12. Sarkolysin
    type
    DRUG
  7. arm Group Labels
    1. Arm I (busulfan, cyclophosphamide, melphalan)
    2. Arm II (busulfan, fludarabine phosphate)
    description
    Given IV or PO
    name
    Mycophenolate Mofetil
    other Names
    1. Cellcept
    2. MMF
    type
    DRUG
  8. arm Group Labels
    1. Arm I (busulfan, cyclophosphamide, melphalan)
    2. Arm II (busulfan, fludarabine phosphate)
    description
    Correlative studies
    name
    Pharmacological Study
    type
    OTHER
  9. arm Group Labels
    1. Arm I (busulfan, cyclophosphamide, melphalan)
    2. Arm II (busulfan, fludarabine phosphate)
    description
    Given IV or PO
    name
    Tacrolimus
    other Names
    1. FK 506
    2. Fujimycin
    3. Hecoria
    4. Prograf
    5. Protopic
    type
    DRUG
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
30
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Probability of Event-free Survival (EFS) for Patients after 18 months. An event is either treatment related mortality (TRM), primary or secondary graft failure, or relapse/non-response (as defined in protocol section 10). Time to event is time from transplant with patients who die between the start of the conditioning regimen and transplant given a time to event of zero.
    measure
    Percent Probability of Event-free Survival (EFS)
    time Frame
    From transplant up to 18 months
  2. description
    The number of patients who experience TRM on day 100. Treatment-Related Mortality (TRM) an event defined as a death prior to relapse or non-response. Time to TRM is defined as time from transplants to TRM. Patients who die between the start of the conditioning regimen and transplant will be considered a TRM with time to TRM of zero.
    measure
    Number of Participants Who Experience Treatment-Related Mortality (TRM) by Day 100
    time Frame
    From transplant up to 100 days
secondary Outcomes
  1. description
    Primary Graft failure is defined as the failure to achieve an ANC \>= 500/uL after 42 days, determined by 3 consecutive measurements on different days; OR \< 5% donor cells in blood or bone marrow by day +42 (as demonstrated by a chimerism assay), without evidence of Juvenile Myelomonocytic Leukemia (JMML).
    measure
    Percentage of Participants Who Experience Primary Graft Failure Event Between Arms
    time Frame
    Day 0 - day 540 (18 months) following completion of stem cell transplant
  2. description
    Probability of patients relapsing at 18 months. A relapse event is defined in protocol section 10.2.3. Time to relapse/non-response is defined as time from transplant to when all criteria of section 10.2.3 are met.
    measure
    Percent Probability of 18 Months-relapse Event Between Arms
    time Frame
    From transplant up to 18 months
Full study description
brief Summary
This randomized phase II trial studies how well giving busulfan, cyclophosphamide, and melphalan or busulfan and fludarabine phosphate before donor hematopoietic cell transplant works in treating younger patients with juvenile myelomonocytic leukemia. Giving chemotherapy before a donor hematopoietic transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient, they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. It is not yet known whether giving busulfan, cyclophosphamide, and melphalan or busulfan and fludarabine phosphate before a donor stem cell transplant is more effective in treating juvenile myelomonocytic leukemia.
detailed Description
PRIMARY OBJECTIVES: I. To compare ? in a randomized fashion ? the day 100 treatment related mortality (TRM) incidence for two myeloablative conditioning regimens, busulfan-fludarabine (fludarabine phosphate) (BU-FLU) and busulfan-cyclophosphamide-melphalan (BU-CY-MEL), prior to hematopoietic cell transplant (HCT) for children with juvenile myelomonocytic leukemia (JMML), in order to determine the preferred regimen for future trials. II. To compare ? in a randomized fashion ? the 18-month event-free survival (EFS) following two different myeloablative conditioning regimens (BU-FLU vs. BU-CY-MEL) prior to HCT for children with JMML, in order to determine the preferred regimen for future trials. SECONDARY OBJECTIVES: I. To determine the 18-month relapse incidence (RI) following two different myeloablative conditioning regimens (BU-FLU vs. BU-CY-MEL) prior to HCT for children with JMML. II. To determine the graft failure rates following two different myeloablative conditioning regimens (BU-FLU vs. BU-CY-MEL) prior to HCT for children with JMML. TERTIARY OBJECTIVES: I. To determine the rates of severe toxicities (grade 3/4) at day 100 post-HCT between the two myeloablative conditioning regimens (BU-FLU vs. BU-CY-MEL). II. To determine the rates of acute and chronic (at 18 months post-HCT) graft-versus-host disease (GVHD) following HCT using two different conditioning regimens (BU-FLU vs. BU-CY-MEL) in children with JMML. III. To create a JMML-specific pre-HCT index to allow better risk-stratification of future patients. IV. To determine the feasibility of assessing post-transplant disease burden by donor chimerism measurements and allele-specific polymerase chain reaction (PCR) in mononuclear and sorted cell subsets. V. To validate gene expression and methylation classifiers predictive of relapse in patients with JMML. VI. To comprehensively assess genetic and biochemical alterations amongst patients with JMML who are treated on this transplant protocol. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: CONDITIONING REGIMEN: Patients receive busulfan intravenously (IV) over 2-3 hours once daily (QD), every 12 hours, or every 6 hours on days -8 to -5, cyclophosphamide IV over 60 minutes QD on days -4 and -3, and melphalan IV over 15-30 minutes on day -1. TRANSPLANT: Patients undergo allogeneic HCT on day 0. Patients receive tacrolimus IV or orally (PO) on days -1 to 98 (related donor) or 180 (unrelated donor) and mycophenolate mofetil IV over 2 hours or PO every 8 hours on days 1-30 (related donor) or 45 (unrelated donor). ARM II: CONDITIONING REGIMEN: Patients receive busulfan as in Arm I and fludarabine phosphate IV over 30-60 minutes on days -5 to -2. TRANSPLANT: Patients undergo allogeneic HCT as in Arm I. Patients receive tacrolimus IV or PO on days -1 to 98 (related donor) or 180 (unrelated donor) and mycophenolate mofetil IV over 2 hours or PO every 8 hours on days 1-30 (related donor) or 45 (unrelated donor). After completion of study treatment, patients are followed up for 5 years.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-b1e843ba818d890137e7
      requested nct id
      NCT01824693
      primary nct id
      NCT01824693
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      cddcd4e3a59550bc78924062a298c359d8f811413f73f4a4461963aecf3790d6
      payload sha256
      f2c31bcdb8ff211be8381b5533127188c930b51062adb27abf78b94c42210eed
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-b1e843ba818d890137e7
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01824693
      occurrences
      1. context exact
        NCT01824693
        end
        11
        exact text
        NCT01824693
        start
        0
      offset unit
      unicode_code_points
      query cond
      Juvenile Myelomonocytic Leukemia
      query disease state id
      ds-juvenile-myelomonocytic-leukemia
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-juvenile-myelomonocytic-leukemia-000.json
      source file sha256
      cddcd4e3a59550bc78924062a298c359d8f811413f73f4a4461963aecf3790d6
      source json pointer
      /studies/154/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      aff6dfa5f2050b5349e6b00ddb765c5292c980d061c3fc645a8886a3e97db1c1

    Preserved source evidence · Not medical advice